Myoview (Tetrofosmin)

Tetrofosmin is a lipophilic cation that readily enters viable heart cells. Its uptake is proportional to regional blood flow, so areas with good perfusion accumulate more tracer. The gamma emissions from the radionuclide are captured by SPECT cameras, producing detailed images of myocardial perfusion.

The administered activity of Myoview is determined by the prescribing physician based on the patient’s weight, the imaging protocol, and regulatory guidelines. Healthcare professionals calculate the appropriate dose to achieve optimal image quality while adhering to radiation safety standards.

Myoview contains a radioactive tracer, so it is generally avoided during pregnancy unless the diagnostic benefit clearly outweighs the potential fetal radiation risk. Breastfeeding is not recommended after administration; mothers should discuss appropriate interruption of nursing with their healthcare provider.

To order Myoview, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and any necessary import documentation.

The primary alternatives for myocardial perfusion imaging are Technetium‑99m sestamibi and Thallium‑201. Compared with Thallium‑201, tetrofosmin offers a lower radiation dose and faster imaging protocols. Relative to Technetium‑99m sestamibi, tetrofosmin provides comparable image quality but may have slightly different biodistribution, which can influence protocol selection.

Myoview must be stored refrigerated between 2 °C and 8 °C, protected from light, and should never be frozen or shaken. Before use, allow the vial to reach room temperature if required by the imaging protocol, and handle it with standard radiopharmacy precautions to avoid contamination.

Myoview is administered as an intravenous injection by a qualified healthcare professional. The dose is injected as a single bolus, followed by a short waiting period to allow myocardial uptake before the patient is positioned for SPECT imaging.

The most serious risks include severe allergic reactions such as anaphylaxis, significant hypotension, and cardiac arrhythmias that may occur during or shortly after injection. Immediate medical attention is required if any of these events are observed.

Myoview should not be used in patients with known hypersensitivity to tetrofosmin or any component of the formulation, in pregnant women unless absolutely necessary, and in individuals where the radiation exposure outweighs the diagnostic benefit, such as certain pediatric cases without clear indication.